Showing 1 to 1 of 1 results
dw.com
🌐 85% Global Worthiness
Brain Tumor Vaccine Shows Promise in Phase 1 Trial
A Phase 1 clinical trial in Heidelberg and Mannheim demonstrated that a new mutation-specific vaccine targeting IDH1 mutations in diffuse gliomas yielded positive results, with 84% of the 33 participants still alive three years after treatment, and 63% showing tumor stabilization.
Brain Tumor Vaccine Shows Promise in Phase 1 Trial
A Phase 1 clinical trial in Heidelberg and Mannheim demonstrated that a new mutation-specific vaccine targeting IDH1 mutations in diffuse gliomas yielded positive results, with 84% of the 33 participants still alive three years after treatment, and 63% showing tumor stabilization.
Progress
40% Bias Score
Good Health and Well-being
Showing 1 to 1 of 1 results